119 related articles for article (PubMed ID: 33061421)
1. LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.
Wang J; Gao J; Chen Q; Zou W; Yang F; Wei C; Wang Z
Onco Targets Ther; 2020; 13():9333-9348. PubMed ID: 33061421
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA receptor activator of nuclear factor-κ B ligand promotes cisplatin resistance in non-small cell lung cancer cells.
Zhu Z; Gong X; Li J; Shi Y; Zhang M
Exp Ther Med; 2021 May; 21(5):518. PubMed ID: 33815591
[TBL] [Abstract][Full Text] [Related]
3. CTBP2 contributes to cisplatin resistance in lung adenocarcinoma by inhibiting generation of reactive oxygen species.
Wang M; Shi L; Fan S; Hu C
Transl Cancer Res; 2024 Apr; 13(4):1695-1706. PubMed ID: 38737699
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
[TBL] [Abstract][Full Text] [Related]
5. Acquired rare recurrent
Lin L; Lu Q; Cao R; Ou Q; Ma Y; Bao H; Wu X; Shao Y; Wang Z; Shen B
Am J Cancer Res; 2020; 10(11):4005-4015. PubMed ID: 33294282
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MALAT1 Regulates the Progression and Cisplatin Resistance of Ovarian Cancer Cells via Modulating miR-1271-5p/E2F5 Axis.
Wang Y; Wang X; Han L; Hu D
Cancer Manag Res; 2020; 12():9999-10010. PubMed ID: 33116856
[TBL] [Abstract][Full Text] [Related]
7. LncRNA LINC01116 Promotes the Development of Colorectal Cancer by Targeting miR-9-5p/STMN1.
Bi C; Cui H; Fan H; Li L
Onco Targets Ther; 2020; 13():10547-10558. PubMed ID: 33116633
[TBL] [Abstract][Full Text] [Related]
8. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINC01116 acts as an oncogene in prostate cancer cells through regulation of miR-744-5p/UBE2L3 axis.
Yu S; Yu H; Zhang Y; Liu C; Zhang W; Zhang Y
Cancer Cell Int; 2021 Mar; 21(1):168. PubMed ID: 33726770
[TBL] [Abstract][Full Text] [Related]
10. LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression.
Meng L; Xing Z; Guo Z; Liu Z
Cell Death Dis; 2020 Dec; 11(12):1063. PubMed ID: 33311496
[TBL] [Abstract][Full Text] [Related]
11. LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma [Retraction].
Onco Targets Ther; 2023; 16():615-616. PubMed ID: 37489157
[TBL] [Abstract][Full Text] [Related]
12. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
Shen JG; Xu SN; Yin LG
Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
[TBL] [Abstract][Full Text] [Related]
13. LncRNAs in non-small cell lung cancer: novel diagnostic and prognostic biomarkers.
Fu J; Yu L; Yan H; Tang S; Wang Z; Dai T; Chen H; Zhang S; Hu H; Liu T; Tang S; He R; Zhou H
Front Mol Biosci; 2023; 10():1297198. PubMed ID: 38152110
[TBL] [Abstract][Full Text] [Related]
14. Construction of subtype classifiers and validation of a prognostic risk model based on hypoxia-associated lncRNAs for lung adenocarcinoma.
Hui H; Li D; Lin Y; Miao H; Zhang Y; Li H; Qiu F; Jiang B
J Thorac Dis; 2023 Jul; 15(7):3919-3933. PubMed ID: 37559652
[TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNAs as potential therapeutic targets in non‑small cell lung cancer (Review).
Tang P; Sun D; Xu W; Li H; Chen L
Int J Mol Med; 2023 Aug; 52(2):. PubMed ID: 37350412
[TBL] [Abstract][Full Text] [Related]
16. LINC01116 affects patient survival differently and is dissimilarly expressed in ER+ and ER- breast cancer samples.
Karimi Taheri M; Ghanbari S; Gholipour A; Givi T; Sadeghizadeh M
Cancer Rep (Hoboken); 2023 Aug; 6(8):e1848. PubMed ID: 37321964
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel prognostic model based on homologous recombination deficiency associated lncRNAs in lung adenocarcinoma.
Liu X; Wang T; Ren Z; Feng C; Tian X
Heliyon; 2023 Apr; 9(4):e14811. PubMed ID: 37089382
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
19. Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma.
Tong F; Xu L; Xu S; Zhang M
Front Genet; 2022; 13():834935. PubMed ID: 36105077
[No Abstract] [Full Text] [Related]
20. Long Non-Coding RNA AP000695.2 Acts as a Novel Prognostic Biomarker and Regulates the Cell Growth and Migration of Lung Adenocarcinoma.
Wang C; Guo J; Jiang R; Wang C; Pan C; Nie Z; Jiang X
Front Mol Biosci; 2022; 9():895927. PubMed ID: 35685240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
